"Short interest in Nektar Therapeutics plummeted by 5.2% or 1,192,549 shares. The final shorts are 16.5% of the total floated shares. The positions dropped from 22,820,073 shares on June 30,2015 to 21,627,524 on July 15,2015."
Sure was a lot of volume going into the close and a runup in price as rest of market was going lower. I had the same opinion as hoyas; when the news was announced that tNKTR was going into the S&P600, i remembered what happened when the Rusell 200 was entered. We had a runup prior to the news and then a pullback; pretty significant actually. This seems and feels different now and I wouldn't be at all surprised to see something really positive announced soon. Could also be the squeeze we have been talking about as the SI kept increasing. We will see....
As I have said over and over again about dc, for instance, do not take anyone or anything they say at face value on a message board; especially those who post regularly and claim no agenda. Simply a waste of time to get drawn into a discussion that they want to control. I have neither the time nor the respect for these posters and very rarely will I even respond anymore.
As for the nitwit who has been trolling here for months, remember this. When he first arrived on the scene in Nov-Dec, he was wildly stating that NKTR was going to the moon; buy, buy, buy. He kept repeating this over and over for a week or two. Then he disappeared and a few weeks later morphed into this idiot with multiple aliases who should have been kicked out of here long ago. This chucklehead is a short, pure and simple; nothing else. A sad life indeed joey(yes, that is his name) lives; but there it is.
On a more constructive note, I was very interested in hearing HR's positive take on the Movantik launch and the ensuing weeks. Remember, NKTR paid 10M to AZN for among other things, the right to look at current sales data and analysis. If he is very positive....that is great news.
"Not that I expect her presentation will have any immediate impact on NKTR's stock price. "
Maybe not, but tomorrow's presentation may very well move the price especially if accompanied by a PR which outlines results presented today as well as an indication of the path to be taken with the FDA.